logo

AKBA

Akebia Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

AKBA fundamentals

Akebia Therapeutics (AKBA) released its earnings on Nov 10, 2025: revenue was 58.76M (YoY +56.99%), beat estimates; EPS was 0 (YoY +100.00%), beat estimates.
Revenue / YoY
58.76M
+56.99%
EPS / YoY
0
+100.00%
Report date
Nov 10, 2025
AKBA Earnings Call Summary for Q3,2025
  • Vafseo launch momentum: $14.3M revenue in Q3, 70,000+ patients with access, but adherence challenges persist.
  • Clinical differentiation: Win-Odds data shows 32% lower mortality/hospitalization risk vs. ESAs.
  • Financial strength: $58.8M total revenue, $166.4M cash, supporting 2026 expansion.
  • Operational progress: DaVita full rollout, USRC protocol adjustments, and 2027 data catalysts.
EPS
Revenue

Revenue & Expenses

AKBA has released its 2025 Q3 earnings report, with revenue of 58.77M, reflecting a YoY change of 57.01%, and net profit of 540.00K, showing a YoY change of 102.69%. The Sankey diagram below clearly presents AKBA's revenue sources and cost distribution.

Key Indicators

Akebia Therapeutics (AKBA) key financial stats and ratios, covering profitability, financial health, and leverage.
Akebia Therapeutics (AKBA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Akebia Therapeutics (AKBA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Akebia Therapeutics (AKBA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Akebia Therapeutics (AKBA) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Akebia Therapeutics (AKBA) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield